DDInter998 DDInter905
Ivermectin is a semi-synthetic antiparasitic medication derived from avermectins, a class of highly-active broad-spectrum antiparasitic agents isolated from the fermentation products of _Streptomyces avermitilis_. Ivermectin itself is a mixture of two avermectins, comprising roughly 90% 5-O-demethyl-22,23-dihydroavermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1a</sub>) and 10% 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro­-25-(1-methylethyl)avermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1b</sub>). Ivermectin is mainly used in humans in the
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
Ivermectin {u} (Compound) binds {v} (Gene) NR1H4
NR1H4 {u} (Gene) is bound by {v} (Compound) Chenodeoxycholic acid
Chenodeoxycholic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Ivermectin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Ivermectin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Ivermectin {u} (Compound) upregulates {v} (Gene) TRAPPC6A
TRAPPC6A {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Ivermectin {u} (Compound) upregulates {v} (Gene) TRIB1
TRIB1 {u} (Gene) is upregulated by {v} (Compound) Simvastatin
Simvastatin {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Ivermectin {u} (Compound) upregulates {v} (Gene) TRIB1
TRIB1 {u} (Gene) is downregulated by {v} (Compound) Methyldopa
Methyldopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Ivermectin {u} (Compound) upregulates {v} (Gene) MAPKAPK5
MAPKAPK5 {u} (Gene) is upregulated by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Ivermectin {u} (Compound) upregulates {v} (Gene) MAPKAPK5
MAPKAPK5 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Ivermectin {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is bound by {v} (Compound) Arsenic trioxide
Arsenic trioxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Ivermectin {u} (Compound) upregulates {v} (Gene) RAP1GAP
RAP1GAP {u} (Gene) is downregulated by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Ivermectin (Compound) binds NR1H4 (Gene) and NR1H4 (Gene) is bound by Chenodeoxycholic acid (Compound) and Chenodeoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Ivermectin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Dasatinib (Compound) and Dasatinib may lead to a major life threatening interaction when taken with Idelalisib
Ivermectin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound) and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Ivermectin (Compound) upregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is upregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Ivermectin (Compound) upregulates TRIB1 (Gene) and TRIB1 (Gene) is upregulated by Simvastatin (Compound) and Simvastatin may lead to a major life threatening interaction when taken with Idelalisib
Ivermectin (Compound) upregulates TRIB1 (Gene) and TRIB1 (Gene) is downregulated by Methyldopa (Compound) and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Ivermectin (Compound) upregulates MAPKAPK5 (Gene) and MAPKAPK5 (Gene) is upregulated by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Ivermectin (Compound) upregulates MAPKAPK5 (Gene) and MAPKAPK5 (Gene) is downregulated by Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Idelalisib
Ivermectin (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is bound by Arsenic trioxide (Compound) and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Ivermectin (Compound) upregulates RAP1GAP (Gene) and RAP1GAP (Gene) is downregulated by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Idelalisib